Report top-line results for the alcoholic hepatitis clinical trial
Delivered after the deadline (68 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 29 Nov 2022
- Due
- 31 Dec 2022
- Delivered
- 9 Mar 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Top-line results in alcoholic hepatitis are expected by the end of 2022.”
What we found
Evidence strength A What the grades mean
The company announced top-line results for the Phase 2 clinical trial of ADX-629 in acute alcoholic hepatitis on March 9, 2023, which is after the end-of-2022 deadline.
-
A Aldeyra Therapeutics, Inc. 8-K filed 2023-03-09
“Positive Top-Line Results Announced from the Phase 2 Clinical Trial of ADX-629 in Acute Alcoholic Hepatitis” ✓ confirmed on the page
Market reaction: the shares moved -1.4% against the S&P 500 over the three sessions around the disclosure (8 Mar 2023 to 13 Mar 2023). What this measures
Checked 2 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +1096 days
- 3 versions
-
Version 1 · original · stated 29 Nov 2022
Deadline 31 Dec 2022 (“by the end of 2022”) · wording expected
-
Version 2 · stated 4 Jan 2024
Deadline 31 Dec 2024 (“in the second half of 2024”) · wording expected
“Top-line results from the Phase 1/2 clinical trial are expected in the second half of 2024.”
-
Version 3 · stated 6 May 2025
Deadline 31 Dec 2025 (“in 2025”) · wording expected
“Open-label Phase 2 clinical trial top-line results expected in 2025”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Top-line results in alcoholic hepatitis
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Aldeyra Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-ALDX-003495 · Corrections policy